Contrast agents are annually administered to millions of patients worldwide [1] . Contrast-induced acute kidney injury (CI-AKI) is the third leading cause of acute kidney injury (AKI) in hospitalized patients, accounting for about 10% of hospital-acquired renal failure [2] . Sodium bicarbonate-based hydration was found to be superior to normal saline in prevention of CI-AKI in several recent meta-analyses [3] [4] [5] [6] [7] [8] . These meta-analyses included up to 18 trials out of a total of 24 currently identified and eligible investigations (Table 1) . Subgroup meta-analyses limited to published trials (full manuscripts after peer review) showed bicarbonate hydration to be superior to normal saline, whereas unpublished studies (presented at meetings with limited peer review and available as abstracts) were controversial, showing either a significant [6] or non-significant decrease in risk of CI-AKI [7, 8] . All meta-analyses demand additional studies to be performed based on the fact that substantial heterogeneity and publication bias were found, as after adjustment for presumed unpublished trials by trim-and-fill analysis, the estimated pooled odds ratios did not reach statistical significance [3] [4] [5] 7] .
However, heterogeneity found in these meta-analyses may be due to factors other than publication status such as differences in peri-procedural hydration protocols or concurrent medications, use of contrast media with varying osmolarity and differences in radiographic procedures. Whereas the imposed risk for AKI by various low-osmolar or iso-osmolar contrast media is still a matter of debate [9, 10] , the type of procedure definitely has consequences for the risk of the patients. Weisbord et al. [11] showed that the incidence of CI-AKI is lower for intravenous contrast application than for arterial angiographies, with significant differences in coronary and non-coronary arteriographs.
In the current issue of Nephrology Dialysis and Transplantation (NDT), Hoste and co-workers [12] present a comprehensive meta-analysis including a total of 18 trials also showing subgroups of both full papers (published) and abstracts (unpublished). The special aspect of this metaanalysis is their separate analysis for non-coronary and coronary procedures as well as acute coronary procedures. A marginally significant beneficial effect of hydration with sodium bicarbonate in coronary procedures was observed, whereas the effect in patients undergoing acute coronary procedures was highly significant. If the benefit of bicarbonate in preventing CI-AKI is real, this may be relevant for daily practice because most hydration protocols using isotonic bicarbonate are using a shortened peri-procedural hydration regimen with a higher volume of 3 ml/kg/h given 1 h before intervention, which turns out extremely useful in the acute care setting.
As mentioned, heterogeneity was observed in all metaanalyses that were previously performed. This may be due to trial selection. For example, heterogeneity may have been augmented by one newer trial [13] that was included in the meta-analysis by Hoste et al. [12] but had been excluded from earlier meta-analyses [3] [4] [5] [6] [7] [8] . That trial did not test the effect of hydration with bicarbonate vs normal saline but compared bicarbonate to normal saline plus acetazolamide given to pharmacologically induce alkalinized urine; furthermore, the study is the only one that was performed in children [13] . On the other hand, another trial that was recently published as a full paper [14] reporting positive effects of isotonic sodium bicarbonate therapy has been neither included in most previous meta-analyses [5] [6] [7] nor in the present NDT study [12] .
None of the published meta-analyses was based on all available studies of bicarbonate therapy (Table 1) . Thus, by combining data on CI-AKI from all the 23 previously selected trials and adding one recent investigation not showing any beneficial effect of bicarbonate [15] , we recalculated the pooled odds ratio (OR) of effect sizes for sodium bicarbonate compared with normal saline as previously described [4] . Of the 24 studies, 11 trials have been published in peer-reviewed journals, whereas 13 studies are as yet unpublished (presented at scientific meetings) . CI-AKI occurred in a total of 148 patients in the 1810 patients of the sodium bicarbonate arms (8.2%) compared with 244 such events in the 1788 subjects treated with normal saline (13.6%). The fixed-effect analysis summary OR was in favour of sodium bicarbonate ( [16, [20] [21] [22] [23] [24] [25] 27, 30, [33] [34] [35] [36] . Assessment of publication bias using a funnel plot indicated slight asymmetry, and this was confirmed by formal testing (rank order correlation or Kendall τ of −0.20, one-tailed P value of 0.090, two-tailed P = 0.190 and Egger's test intercept of −1.29, 95% CI of −2.51 to −0.07 with one-tailed P value of 0.019, two-tailed P = 0.039). These tests suggest that the results of this meta-analysis were influenced by a larger treatment effect seen in smaller studies. The imputed OR for CI-AKI using the random-effects model was 0.72 (95% CI 0.57-0.91). The classic fail-safe N was 108, suggesting that 108 additional negative studies would be needed to invalidate the results of this meta-analysis. Applying the much more conservative variant of this method, Orwin's fail-safe N, assuming a mean OR of 2.7 against bicarbonate in unpublished studies (as observed in the included trial with an extreme negative result for bicarbonate [33] ), indicates that eight such trials would be necessary to nullify the overall beneficial effect of sodium bicarbonate.
By their approach to separately analyse published and unpublished trials, Hoste et al. [12] nicely demonstrated that the approach to include unpublished trials (published only as abstracts) as done in several recent meta-analyses in order to reduce publication bias may be problematic. The overall magnitude of CI-AKI reduction was clearly greater in published studies compared with unpublished Table 1 . Trials included in recently published meta-analyses and one additional recently published study on the use of sodium bicarbonate-based hydration to prevent contrast media-induced nephropathy (n = 24) Meta-analysis 
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Nephrol Dial Transplant (2010) 25: Editorial Commentsstudies. Even after inclusion of all available unpublished data, formal testing indicates a likelihood of more unpublished data. The treatment effect based on imputed estimated unpublished studies still supports superiority of sodium bicarbonate. On the other hand, the inclusion of many unpublished studies to overcome the problem of publication bias does not eliminate heterogeneity and introduces the possibility of incorporating lower-quality data. Another approach to overcome heterogeneity may be the selection of studies based on stringent predefined criteria, as done in a recent meta-analysis [37] . However, depending on criteria applied (e.g. exclusion of studies terminated early for benefit [37] ), studies may be eliminated which potentially carry important information. Finally, based on a larger number of trials, this editorial's updated meta-analysis including 24 randomized controlled trials with 3598 patients corroborates and extends the main conclusions of most prior meta-analyses in the field showing that peri-procedural hydration with sodium bicarbonate reduced the incidence of CI-AKI compared with hydration with normal saline. The diminished risk for CI-AKI found in the meta-analysis by Hoste et al. [12] as well as those previously published [4] [5] [6] [7] [8] did not seem to translate into a decreased incidence of death or need for haemodialysis. Two major reasons may account for this dissociation between rate of CI-AKI and need for renal replacement therapy or mortality: first, the patient population enrolled in these studies was at low risk of adverse events and, with such low event rates, even a pooled analysis is underpowered to detect a significant difference; second, very few studies provide long-term follow-up data which is particularly true for the high number of unpublished results [14, 20, 21, [24] [25] [26] 28, 29, 31, 32] . Consequently, even performing more meta-analyses will not answer the question about the efficacy of bicarbonate in adequately preventing CI-AKI. Larger trials with clearly defined endpoints are required to fulfil this task.
In summary, with the exception of one meta-analysis using special selection criteria [37] , sodium bicarbonate-based hydration was found to be superior to normal saline in the prevention of CI-AKI in all recent meta-analyses that significantly differed in single trials that were included [5, 6, 12] . Inclusion of many unpublished studies with the intention to overcome the problem of publication bias does not resolve the problem of heterogeneity but introduces the possibility of including lower-quality data. The lack of any randomized controlled trial to date showing superiority of saline-based hydration at a statistically significant level may suggest that sodium bicarbonate-based hydration should be considered the optimal hydration in high-risk patients undergoing exposure to iodine-based contrast media. Before a firm recommendation for clinical practice can be made, however, publication in full of unpublished studies must be demanded and particular focus on sources of heterogeneity (hydration protocols, contrast media with varying osmolarity as well as indications and radiographic procedures) must be taken into account for future meta-analyses. However, in the end, only adequately powered randomized controlled trials analysing the effects of sodium bicarbonate on clinically meaningful outcomes (e.g. need for dialysis or death) will be able to answer the question about the optimal hydration strategy in high-risk patients for prevention of CI-AKI.
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Focal and segmental glomerulosclerosis (FSGS) is a common cause of end stage renal disease (ESRD), accounting for up to 20% of dialysis patients [1, 2] . FSGS may be clarified as primary, i.e. without known inciting injury, or secondary. Secondary FSGS can occur in association with, e.g. hypertension, reflux nephropathy, obesity, HIV infection, sickle cell disorder, and immune complex diseases [3] [4] [5] . Up to 18% of primary FSGS cases are due to familial disease, while others have been considered idiopathic FSGS [6] . Dai et al. now report on additional genetic variations in patients with FSGS [7] . How then can we approach the classification and understanding of 'genetic' vs 'idiopathic' FSGS? Recently, mutations have been found in several podocyte-associated genes including NPHS1, NPHS2, WT1 and ACTN4 in patients both in familial and sporadic FSGS. The frequency of detection of such genetic alteration in FSGS depends on race and age. The gene encoding podocin (NPHS2) is responsible for an autosomal recessive form of steroid-resistant nephrotic syndrome (SRNS) presenting in childhood [8, 9] and is common in this patient population. More recently, podocin mutations have been found in late-onset familial FSGS [10] . Mutations in α-actinin-4 (ACTN4) or transient receptor potential 6 (TRPC6) cause rare cases of dominantly inherited adult-onset familial FSGS with variable penetrance, but so far have not been found to be a major cause of sporadic causes of FSGS in either adults or children [11, 12] . Overall, polymorphisms/mutations have been found more rarely in patients with adult-onset sporadic FSGS, compared to children with FSGS. Furthermore, NPHS2 mutations and polymorphisms have been rarely found in sporadic FSGS in African-American and European-American populations [13] . In another detailed study of ACTN4 gene mutations in sporadic FSGS patients, only one disease-causing mutation (W59R) was reported and no clinically related single-nucleotide polymorphisms have been found [6] . Heterozygous variants in the promoter regions for ACTN4 or synaptopodin (SYN-PO) were found in five of 82 patients with apparent idiopathic, sporadic FSGS, with no such variants in healthy controls [7] . The current paper by Dai et al. expands investigation of such possible genetic contributions to FSGS by examining alterations of promoter sequences in several podocyte-associated genes, with functional assessment of the possible impact of these genetic changes. These findings expand previous findings by the same group of a new mutation in ACTN4 (184T>A) in the same Chinese population [14] . Of note, these studies do not prove a causal link of promoter variants to disease phenotype. Although functional studies in vitro support that these variants affect expression, further study will be needed to more definitively prove that these disease-associated variants are also diseasecausing. Nevertheless, these studies suggest the possibility that mutations of podocyte-associated genes may exist, albeit rarely, in some adult patients with sporadic 'idiopathic' FSGS, as well as in familial adult-onset FSGS, and more commonly, in children with SRNS and FSGS. The spectrum of genetic alterations in FSGS appears to vary in different patient groups and in animal models vs humans. Importantly, experimentally, podocyte-specific ACTN4 K228E mutant mice develop significant proteinuria and FSGS-like lesions, confirming the proof-of-concept that one mutation site of one podocyte-associated gene can lead to disease [15] . However, single-gene mutation induction of FSGS is rare in adult patients, and so far, although more common in children, is still present in only a minority of children with FSGS. ACTN4 W59R mutation has been associated with FSGS in one patient, with abnormal α-actinin-4 location and increased actin-binding shown with this mutation in vitro [6] . In contrast, the R229Q variant of the NPHS2 gene alone is insufficient to cause FSGS, but appears to enhance susceptibility to renal injury in the
